These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 19705345

  • 1. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes.
    Foley JE, Sreenan S.
    Horm Metab Res; 2009 Dec; 41(12):905-9. PubMed ID: 19705345
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Update: vildagliptin for the treatment of Type 2 diabetes.
    Garber AJ, Sharma MD.
    Expert Opin Investig Drugs; 2008 Jan; 17(1):105-13. PubMed ID: 18095923
    [Abstract] [Full Text] [Related]

  • 8. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
    Schweizer A, Dejager S, Bosi E.
    Diabetes Obes Metab; 2009 Aug; 11(8):804-12. PubMed ID: 19476473
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
    Xiaoyan C, Jing W, Xiaochun H, Yuyu T, Shunyou D, Yingyu F.
    Curr Med Res Opin; 2016 Jun; 32(6):1131-6. PubMed ID: 26950829
    [Abstract] [Full Text] [Related]

  • 13. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
    Mikhail N.
    Vasc Health Risk Manag; 2008 Jun; 4(6):1221-7. PubMed ID: 19337535
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
    Foley JE, Bhosekar V, Kawamori R.
    Vasc Health Risk Manag; 2016 Jun; 12():9-12. PubMed ID: 26855580
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study.
    Ji LN, Pan CY, Lu JM, Li H, Li Q, Li QF, Peng YD, Tian HM, Yao C, Zhao ZG, Zhang RY, Wang XL, Wang L, VISION Study Group.
    Cardiovasc Diabetol; 2013 Aug 19; 12():118. PubMed ID: 23958390
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.